Gilead's long-acting HIV drug superior to daily pill Truvada in study

 Gilead Sciences (GILD.O) said on Thursday a late-stage study showed its injectable drug, lenacapavir, was more effective in preventing HIV infection in women compared to the company's existing daily pill Truvada.